Tu1871: REAL-WORLD EFFICACY AND SAFETY OF JANUS KINASE INHIBITORS (JAKI) IN INFLAMMATORY BOWEL DISEASE (IBD) WITH EXTRAINTESTINAL MANIFESTATIONS (EIMS): A COLOMBIAN EXPERIENCE WITH UPADACITINIB AND TOFACITINIB - JAKEIM-IBD | Publicación